Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Axitinib in advanced renal cell carcinoma: real-life data and dose modification audit

Rosemeen Parkar and Ekaterini Boleti
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.19-2-s54
Clin Med March 2019
Rosemeen Parkar
Medical Oncology, Royal Free Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ekaterini Boleti
Medical Oncology, Royal Free Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Aims

  1. To assess the general tolerability of axitinib use in advanced renal cell carcinoma in a real-world setting.

  2. To audit our axitinib dose modification practice.

Methods

Using our electronic patient records and prescribing systems, 43 patients with advanced renal cell carcinoma, who had received axitinib between the years 2014 and 2017, were identified.

Results

31 patients had clear cell carcinoma, 11 had papillary carcinoma, and one had extensive sarcomatoid features. There were 17 women and 26 men between the ages of 37 and 86 years (median of 69 years).

Five patients received axitinib as first-line treatment within the A PREDICT trial. 33 patients received axitinib as second-line treatment, having had sunitinib (n=17), pazopanib (n=14), everolimus (n=1) or interferon alpha (n=1) as their first-line treatment.

Four patients had axitinib as their third-line treatment and one as their fourth-line treatment after failure of previous systemic treatments.

39 patients (90.7%) were commenced on the 5 mg twice daily dose of axitinib, three (6.9%) on 3 mg due to borderline performance status, and one on 7 mg for reasons not documented. Fatigue, hypothyroidism, hypertension and anorexia were the most commonly reported side effects. 28 patients (65%) reported fatigue, with 18 (41.9%) requiring either treatment breaks or steroid use. 20 patients (46.5%) had clinical and biochemical hypothyroidism requiring treatment. 14 patients (32.5%) had reported grade 2–3 hypertension requiring treatment. Grade 1–2 diarrhoea was reported in seven patients (16.3%). Two patients (4.65%) had a grade 2 palmar–plantar syndrome.

Doses were escalated in 15 cases only. The maximum dose of 10 mg was reached in only two cases. Dose reduction was reported in 13 cases, mainly due to grade 3 diarrhoea and fatigue. In the remaining 15 patients (34.8%), who had experienced grade 1 side effects, no dose modifications were made.

Conclusions

Side effects experienced by our patients are similar to those in the summary of product characteristics. Patients were commenced on appropriate dosing schedules, but a group of patients would have benefited from a dose escalation. Review points are being added to the electronic prescribing system to ensure that doses are modified appropriately.

Conflict of interest statement

None.

  • © Royal College of Physicians 2019. All rights reserved.
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Axitinib in advanced renal cell carcinoma: real-life data and dose modification audit
Rosemeen Parkar, Ekaterini Boleti
Clinical Medicine Mar 2019, 19 (Suppl 2) s54; DOI: 10.7861/clinmedicine.19-2-s54

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Axitinib in advanced renal cell carcinoma: real-life data and dose modification audit
Rosemeen Parkar, Ekaterini Boleti
Clinical Medicine Mar 2019, 19 (Suppl 2) s54; DOI: 10.7861/clinmedicine.19-2-s54
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Aims
    • Methods
    • Results
    • Conclusions
    • Conflict of interest statement
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Adherence to therapy in chronic inflammatory rheumatic diseases: the older the better
  • A review in general practice: the appropriate prescription of PPIs with those taking aspirin over the age of 70
  • A rare case of ascites
Show more Clinical

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians